Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 4/20 | 0.38 |
| ▸ | CETP | P11597 | 7/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 3/20 | 0.38 |
| ▸ | CLK1 | P49759 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.36 |
| ▸ | VSIR | Q9H7M9 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24821906 | 0.93 | HPGD (0.39) | HPGDTP53MAPTCLK1SMN1; SMN2 | |
| SCHEMBL30153089 | 0.93 | HPGD (0.39) | HPGDTP53MAPTCLK1SMN1; SMN2 | |
| SCHEMBL24820726 | 0.92 | LMNA (0.39) | HPGDTP53CETPMAPTCLK1 | |
| SCHEMBL30153217 | 0.92 | HPGD (0.38) | HPGDTP53CETPMAPTTHRB | |
| SCHEMBL24820660 | 0.92 | HPGD (0.38) | HPGDTP53CETPMAPTTHRB | |
| SCHEMBL24818876 | 0.92 | CLK1 (0.43) | HPGDTP53MAPTTHRBCLK1 | |
| SCHEMBL30152937 | 0.92 | LMNA (0.39) | HPGDTP53CETPMAPTCLK1 | |
| SCHEMBL24820662 | 0.91 | HPGD (0.37) | HPGDTP53MAPTTHRBCLK1 | |
| SCHEMBL24821895 | 0.91 | HPGD (0.37) | HPGDTP53CETPMAPTTHRB | |
| SCHEMBL24818673 | 0.91 | HPGD (0.37) | HPGDTP53CETPMAPTCLK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. | 2025-05-22 | — | — | US | disclosed |
| EP-4359381-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-05-01 | — | — | EP | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
| WO-2022272248-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163038-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | HPGD 4374/4885TP53 378/4885CETP 3617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.